Skip to main content
Premium Trial:

Request an Annual Quote

Pathline Emerge Begins Using GenomOncology Molecular Testing Workflow

NEW YORK (GenomeWeb) – GenomOncology announced today that pathology services company Pathline Emerge has begun using its GO Clinical Workbench for analysis and reporting of next-generation sequencing tests.

Financial terms of the deal were not disclosed.

Pathline partnered with GenomOncology in order to find ways to streamline its workflows and deliver detailed reports to clinicians, the company said in a statement. The GO Clinical Workbench enables labs to configure workflows for molecular tests based on NGS, FISH, karyotyping, RT-PCR, IHC, and others. Specifically, labs can perform quality control analysis, evaluate all variants, and send clinical reports.

"One key area of value creation is being able to provide oncologists with reports that provide decision support over integrated data sets," said GenomOncology President and CEO Manuel Glynias in a statement. "Therapy decisions can change depending on co-occurring genomic aberrations and it's important for the oncologist to understand these potential changes — for example, combining gene fusion data with karyotype results, SNVs, and indels to provide an integrated interpretative report that proposes therapeutic options and suggests appropriate clinical trials."

In November, GenomOncology announced a deal to comarket ArcherDx's next-generation sequencing assays alongside the GO Clinical Workbench, and to support interpretation of several ArcherDx assays, including the ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung panels.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.